InsidersTradesSigma
Track the Quanterix Corp share price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Quanterix Corp has logged 364 reports. Market capitalisation: €147.6m. The latest transaction was reported on 20 August 2026 (Levée d'options). Among the most active insiders: Toloue Masoud. Every trade is openly available.
364
Insider Decl.
n/a
Thresholds
€7m
15 ops.
Buy Volume
€3m
86 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Quanterix Corp Hold (neutral), based on 3 analysts. Average price target: US$3.00.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,032 of 29,056 companies
13.4
score / 100
Value2
Quality24
FCF yld-64%
Earn yld-86%
EV/EBITDA·
ROE-46%
Gross mgn47%
Net mgn-77%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations364 total
3,955 sharesCommon StockSEC:0001689757-26-000005:0
2,802 sharesCommon StockSEC:0001207928-26-000009:0
25 shares@ US$2.590.0001% mcap1.3% of flowCommon StockSEC:0002120516-26-000015:1
41 shares@ US$2.590.0001% mcap2.1% of flowCommon StockSEC:0002120516-26-000015:3
41 shares@ US$2.590.0001% mcap2.1% of flowCommon StockSEC:0002120516-26-000015:5
111 shares@ US$2.590.0002% mcap5.7% of flowCommon StockSEC:0002120516-26-000015:7
834 sharesCommon StockSEC:0002120516-26-000015:8
249 shares@ US$2.590.0005% mcap12.8% of flowCommon StockSEC:0002120516-26-000015:9
81 sharesCommon StockSEC:0002120516-26-000015:0
136 sharesCommon StockSEC:0002120516-26-000015:2
135 sharesCommon StockSEC:0002120516-26-000015:4
372 sharesCommon StockSEC:0002120516-26-000015:6
72,245 shares@ US$2.930.15% mcap14.5% of flowCommon StockSEC:0001207928-26-000008:1
Canonical exit: 11 Nov 2026 (T+90)
27,155 shares@ US$2.750.054% mcap5.1% of flowCommon StockSEC:0001207928-26-000008:0
Canonical exit: 10 Nov 2026 (T+90)
130 sharesCommon StockSEC:0002120516-26-000014:0
39 shares@ US$3.480.0001% mcap3.6% of flowCommon StockSEC:0002120516-26-000014:1
81 sharesCommon StockSEC:0002120516-26-000013:0
25 shares@ US$4.240.0001% mcap2.7% of flowCommon StockSEC:0002120516-26-000013:1
41 shares@ US$4.240.0001% mcap4.4% of flowCommon StockSEC:0002120516-26-000013:3
41 shares@ US$4.240.0001% mcap4.4% of flowCommon StockSEC:0002120516-26-000013:5
135 sharesCommon StockSEC:0002120516-26-000013:4
136 sharesCommon StockSEC:0002120516-26-000013:2
372 sharesCommon StockSEC:0002120516-26-000013:6
834 sharesCommon StockSEC:0002120516-26-000013:8
111 shares@ US$4.240.0003% mcap11.9% of flowCommon StockSEC:0002120516-26-000013:7
25 of 364 declarations
关于 Quanterix Corp
Quanterix Corp. (NASDAQ: QTRX) 是一家总部位于美国马萨诸塞州比尔里卡的生命科学公司。对于国际投资者而言，该公司处于生物标志物科学、诊断学和转化研究的交汇点。Quanterix 成立于2007年，其特许经营权围绕其专有的 Simoa® 平台构建，该平台旨在检测和量化血液、血清、血浆和其他生物体液中极低浓度的蛋白质。这种超灵敏度是其投资案例的核心，也是其与更传统测量技术区分的基础。（[quanterix.com](https://www.quanterix.com/about-us/)） Quanterix 的商业模式以仪器、耗材、检测试剂盒和相关服务为中心。其客户群涵盖学术研究机构、参考实验室、生物制药公司和诊断开发商。该公司的产品包括 Simoa 分析仪和用于生物标志物发现、临床研究和新兴诊断工作流程的检测试剂盒。管理层将 Quanterix 定位为“从发现到诊断”的平台，在神经退行性疾病研究领域拥有特别强大的影响力，在该领域，敏感的生物标志物检测对于阿尔茨海默病及相关疾病至关重要。（[ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-expands-reach-ivd-and-large-reference-labs)） 从竞争角度来看，Quanterix 是一家专业的科技领导者，而非广泛的诊断综合企业。其护城河来自于技术灵敏度、有意义的装机量和大量的科学验证记录。该公司表示，其技术已获得超过3,400篇同行评审出版物的支持，这有助于增强其在研究界的信誉。在地理上，Quanterix 在北美和几个欧洲国家直接销售，同时通过分销合作伙伴在全球范围内接触客户。（[ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-second-quarter-2025)） 近期一项重要的战略发展是2025年收购 Akoya Biosciences，这使 Quanterix 扩展到空间生物学和具有单细胞分辨率的多重组织成像领域。合并后的平台旨在连接基于血液和基于组织的生物学，扩大 Quanterix 在神经病学、免疫学和肿瘤学方面的可寻址机会。2025年，该公司还强调了在中国和韩国等市场的监管和商业进展，以及支持阿尔茨海默病检测基础设施的新合作。（[ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-launches-novel-p-tau-205-and-p-tau-212-assays-advance?utm_source=openai)） 对于投资者而言，Quanterix 仍然是一个在美国纳斯达克上市的专业增长型公司，面临研究资金周期和制药支出的影响，但其差异化平台定位于精准医疗应用。（[ir.quanterix.com](https://ir.quanterix.com/news-releases/news-release-details/quanterix-releases-financial-results-first-quarter-2025?utm_source=openai)）
